| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.0095 | 0.8 |
| mRNA | AM-580 | CTRPv2 | pan-cancer | AAC | -0.0096 | 0.8 |
| mRNA | PF-573228 | CTRPv2 | pan-cancer | AAC | 0.0087 | 0.8 |
| mRNA | BRD-K07442505 | CTRPv2 | pan-cancer | AAC | 0.0095 | 0.8 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | 0.0093 | 0.9 |
| mRNA | ABT-888 | CTRPv2 | pan-cancer | AAC | 0.009 | 0.9 |
| mRNA | Doxorubicin | FIMM | pan-cancer | AAC | 0.027 | 0.9 |
| mRNA | BRD-A02303741:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0087 | 0.9 |
| mRNA | Epothilone B | GDSC1000 | pan-cancer | AAC | 0.0072 | 0.9 |
| mRNA | BRD4132 | CTRPv2 | pan-cancer | AAC | 0.0083 | 0.9 |